Global Soliris (Eculizumab) Supply, Demand and Key Producers, 2026-2032
The global Soliris (Eculizumab) market size is expected to reach $ 1294 million by 2032, rising at a market growth of -3.2% CAGR during the forecast period (2026-2032).
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.In 2025, global Soliris (Eculizumab) production reached approximately 339 k units.The average gross profit margin of this product is 65%.
The core opportunity for Soliris lies in the expanding clinical value of complement biology across rare diseases, autoimmune disorders, neuroimmunology, and kidney diseases. As physicians gain a deeper understanding of complement-mediated mechanisms, high-risk patients once scattered across hematology, nephrology, neurology, and intensive care are being identified earlier, supporting the expansion of targeted complement therapy from classic rare indications into broader immune-inflammatory settings. Corporate annual reports and regulatory documents show that Soliris has become a key benchmark for the commercialization of complement inhibitors. Its value is not limited to product revenue, but also extends to rare disease care pathways, patient screening, long-term treatment management, and global market access capabilities. For CEOs, marketing leaders, and investors, eculizumab represents an innovative biologics segment where high barriers, strong clinical value, and substantial willingness to pay coexist.The main challenges come from reimbursement pressure, competitive innovation, biosimilar entry, and safety management. As a high-value rare disease therapy, Soliris faces commercial constraints related to treatment cost and reimbursement access. At the same time, long-acting C5 inhibitors, subcutaneous complement drugs, alternative pathway inhibitors, and biosimilars are reshaping the competitive landscape. Clinically, complement inhibition requires strict management of risks such as meningococcal infection, meaning patients often require vaccination, risk education, and continuous monitoring. Because the target diseases involve limited patient populations, complex diagnostic pathways, and high demand for multidisciplinary collaboration, companies must continue investing in medical education, patient identification, real-world evidence, and payer communication to sustain lifecycle value.Downstream demand is shifting from rescue treatment for critically ill patients toward early diagnosis, early treatment, and long-term disease control. Hematology, nephrology, neurology, pediatrics, rheumatology, immunology, and rare disease centers now evaluate eculizumab not only through efficacy, but also through patient stratification, disease progression management, quality-of-life improvement, and long-term safety. As rare disease networks, genetic testing, complement testing, and multidisciplinary consultation systems mature, more potential patients may enter standardized treatment pathways. At the same time, patients and payers are placing greater emphasis on dosing convenience, treatment continuity, real-world benefit, and total healthcare cost control, encouraging companies to build a more complete ecosystem around drugs, diagnostics, follow-up, patient support, and access solutions.
This report studies the global Soliris (Eculizumab) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Soliris (Eculizumab) and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Soliris (Eculizumab) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Soliris (Eculizumab) total production and demand, 2021-2032, (K Units)
Global Soliris (Eculizumab) total production value, 2021-2032, (USD Million)
Global Soliris (Eculizumab) production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Soliris (Eculizumab) consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Soliris (Eculizumab) domestic production, consumption, key domestic manufacturers and share
Global Soliris (Eculizumab) production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Soliris (Eculizumab) production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Soliris (Eculizumab) production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Soliris (Eculizumab) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alexion, AstraZeneca, Samsung Bioepis, Amgen, Epirus Biopharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Soliris (Eculizumab) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Soliris (Eculizumab) Market, By Region:
1. How big is the global Soliris (Eculizumab) market?
2. What is the demand of the global Soliris (Eculizumab) market?
3. What is the year over year growth of the global Soliris (Eculizumab) market?
4. What is the production and production value of the global Soliris (Eculizumab) market?
5. Who are the key producers in the global Soliris (Eculizumab) market?
6. What are the growth factors driving the market demand?
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.In 2025, global Soliris (Eculizumab) production reached approximately 339 k units.The average gross profit margin of this product is 65%.
The core opportunity for Soliris lies in the expanding clinical value of complement biology across rare diseases, autoimmune disorders, neuroimmunology, and kidney diseases. As physicians gain a deeper understanding of complement-mediated mechanisms, high-risk patients once scattered across hematology, nephrology, neurology, and intensive care are being identified earlier, supporting the expansion of targeted complement therapy from classic rare indications into broader immune-inflammatory settings. Corporate annual reports and regulatory documents show that Soliris has become a key benchmark for the commercialization of complement inhibitors. Its value is not limited to product revenue, but also extends to rare disease care pathways, patient screening, long-term treatment management, and global market access capabilities. For CEOs, marketing leaders, and investors, eculizumab represents an innovative biologics segment where high barriers, strong clinical value, and substantial willingness to pay coexist.The main challenges come from reimbursement pressure, competitive innovation, biosimilar entry, and safety management. As a high-value rare disease therapy, Soliris faces commercial constraints related to treatment cost and reimbursement access. At the same time, long-acting C5 inhibitors, subcutaneous complement drugs, alternative pathway inhibitors, and biosimilars are reshaping the competitive landscape. Clinically, complement inhibition requires strict management of risks such as meningococcal infection, meaning patients often require vaccination, risk education, and continuous monitoring. Because the target diseases involve limited patient populations, complex diagnostic pathways, and high demand for multidisciplinary collaboration, companies must continue investing in medical education, patient identification, real-world evidence, and payer communication to sustain lifecycle value.Downstream demand is shifting from rescue treatment for critically ill patients toward early diagnosis, early treatment, and long-term disease control. Hematology, nephrology, neurology, pediatrics, rheumatology, immunology, and rare disease centers now evaluate eculizumab not only through efficacy, but also through patient stratification, disease progression management, quality-of-life improvement, and long-term safety. As rare disease networks, genetic testing, complement testing, and multidisciplinary consultation systems mature, more potential patients may enter standardized treatment pathways. At the same time, patients and payers are placing greater emphasis on dosing convenience, treatment continuity, real-world benefit, and total healthcare cost control, encouraging companies to build a more complete ecosystem around drugs, diagnostics, follow-up, patient support, and access solutions.
This report studies the global Soliris (Eculizumab) production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Soliris (Eculizumab) and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Soliris (Eculizumab) that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Soliris (Eculizumab) total production and demand, 2021-2032, (K Units)
Global Soliris (Eculizumab) total production value, 2021-2032, (USD Million)
Global Soliris (Eculizumab) production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Soliris (Eculizumab) consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Soliris (Eculizumab) domestic production, consumption, key domestic manufacturers and share
Global Soliris (Eculizumab) production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Soliris (Eculizumab) production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Soliris (Eculizumab) production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Soliris (Eculizumab) market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alexion, AstraZeneca, Samsung Bioepis, Amgen, Epirus Biopharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Soliris (Eculizumab) market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Soliris (Eculizumab) Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Plasma Exchange
- Plasma Infusion
- Paroxysmal Nocturnal Hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Other
- Pre-filled Injections
- Vials
- Hospital Infusion Therapy
- Long-term Maintenance Therapy
- Other
- Alexion
- AstraZeneca
- Samsung Bioepis
- Amgen
- Epirus Biopharmaceuticals
1. How big is the global Soliris (Eculizumab) market?
2. What is the demand of the global Soliris (Eculizumab) market?
3. What is the year over year growth of the global Soliris (Eculizumab) market?
4. What is the production and production value of the global Soliris (Eculizumab) market?
5. Who are the key producers in the global Soliris (Eculizumab) market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Soliris (Eculizumab) Introduction
1.2 World Soliris (Eculizumab) Supply & Forecast
1.2.1 World Soliris (Eculizumab) Production Value (2021 & 2025 & 2032)
1.2.2 World Soliris (Eculizumab) Production (2021-2032)
1.2.3 World Soliris (Eculizumab) Pricing Trends (2021-2032)
1.3 World Soliris (Eculizumab) Production by Region (Based on Production Site)
1.3.1 World Soliris (Eculizumab) Production Value by Region (2021-2032)
1.3.2 World Soliris (Eculizumab) Production by Region (2021-2032)
1.3.3 World Soliris (Eculizumab) Average Price by Region (2021-2032)
1.3.4 North America Soliris (Eculizumab) Production (2021-2032)
1.3.5 Europe Soliris (Eculizumab) Production (2021-2032)
1.3.6 China Soliris (Eculizumab) Production (2021-2032)
1.3.7 Japan Soliris (Eculizumab) Production (2021-2032)
1.3.8 India Soliris (Eculizumab) Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Soliris (Eculizumab) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Soliris (Eculizumab) Major Market Trends
2 DEMAND SUMMARY
2.1 World Soliris (Eculizumab) Demand (2021-2032)
2.2 World Soliris (Eculizumab) Consumption by Region
2.2.1 World Soliris (Eculizumab) Consumption by Region (2021-2026)
2.2.2 World Soliris (Eculizumab) Consumption Forecast by Region (2027-2032)
2.3 United States Soliris (Eculizumab) Consumption (2021-2032)
2.4 China Soliris (Eculizumab) Consumption (2021-2032)
2.5 Europe Soliris (Eculizumab) Consumption (2021-2032)
2.6 Japan Soliris (Eculizumab) Consumption (2021-2032)
2.7 South Korea Soliris (Eculizumab) Consumption (2021-2032)
2.8 ASEAN Soliris (Eculizumab) Consumption (2021-2032)
2.9 India Soliris (Eculizumab) Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Soliris (Eculizumab) Production Value by Manufacturer (2021-2026)
3.2 World Soliris (Eculizumab) Production by Manufacturer (2021-2026)
3.3 World Soliris (Eculizumab) Average Price by Manufacturer (2021-2026)
3.4 Soliris (Eculizumab) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Soliris (Eculizumab) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Soliris (Eculizumab) in 2025
3.5.3 Global Concentration Ratios (CR8) for Soliris (Eculizumab) in 2025
3.6 Soliris (Eculizumab) Market: Overall Company Footprint Analysis
3.6.1 Soliris (Eculizumab) Market: Region Footprint
3.6.2 Soliris (Eculizumab) Market: Company Product Type Footprint
3.6.3 Soliris (Eculizumab) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Soliris (Eculizumab) Production Value Comparison
4.1.1 United States VS China: Soliris (Eculizumab) Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Soliris (Eculizumab) Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Soliris (Eculizumab) Production Comparison
4.2.1 United States VS China: Soliris (Eculizumab) Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Soliris (Eculizumab) Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Soliris (Eculizumab) Consumption Comparison
4.3.1 United States VS China: Soliris (Eculizumab) Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Soliris (Eculizumab) Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Soliris (Eculizumab) Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.4.3 United States Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
4.5 China Based Soliris (Eculizumab) Manufacturers and Market Share
4.5.1 China Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.5.3 China Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
4.6 Rest of World Based Soliris (Eculizumab) Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Soliris (Eculizumab) Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Plasma Exchange
5.2.2 Plasma Infusion
5.3 Market Segment by Type
5.3.1 World Soliris (Eculizumab) Production by Type (2021-2032)
5.3.2 World Soliris (Eculizumab) Production Value by Type (2021-2032)
5.3.3 World Soliris (Eculizumab) Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY COMPLEMENT PATHWAY TARGET
6.1 World Soliris (Eculizumab) Market Size Overview by Complement Pathway Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Complement Pathway Target
6.2.1 Paroxysmal Nocturnal Hemoglobinuria
6.2.2 Atypical Hemolytic Uremic Syndrome
6.2.3 Other
6.3 Market Segment by Complement Pathway Target
6.3.1 World Soliris (Eculizumab) Production by Complement Pathway Target (2021-2032)
6.3.2 World Soliris (Eculizumab) Production Value by Complement Pathway Target (2021-2032)
6.3.3 World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2032)
7 MARKET ANALYSIS BY PACKAGE
7.1 World Soliris (Eculizumab) Market Size Overview by Package: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Package
7.2.1 Pre-filled Injections
7.2.2 Vials
7.3 Market Segment by Package
7.3.1 World Soliris (Eculizumab) Production by Package (2021-2032)
7.3.2 World Soliris (Eculizumab) Production Value by Package (2021-2032)
7.3.3 World Soliris (Eculizumab) Average Price by Package (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Soliris (Eculizumab) Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Infusion Therapy
8.2.2 Long-term Maintenance Therapy
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Soliris (Eculizumab) Production by Application (2021-2032)
8.3.2 World Soliris (Eculizumab) Production Value by Application (2021-2032)
8.3.3 World Soliris (Eculizumab) Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Alexion
9.1.1 Alexion Details
9.1.2 Alexion Major Business
9.1.3 Alexion Soliris (Eculizumab) Product and Services
9.1.4 Alexion Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Alexion Recent Developments/Updates
9.1.6 Alexion Competitive Strengths & Weaknesses
9.2 AstraZeneca
9.2.1 AstraZeneca Details
9.2.2 AstraZeneca Major Business
9.2.3 AstraZeneca Soliris (Eculizumab) Product and Services
9.2.4 AstraZeneca Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 AstraZeneca Recent Developments/Updates
9.2.6 AstraZeneca Competitive Strengths & Weaknesses
9.3 Samsung Bioepis
9.3.1 Samsung Bioepis Details
9.3.2 Samsung Bioepis Major Business
9.3.3 Samsung Bioepis Soliris (Eculizumab) Product and Services
9.3.4 Samsung Bioepis Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Samsung Bioepis Recent Developments/Updates
9.3.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.4 Amgen
9.4.1 Amgen Details
9.4.2 Amgen Major Business
9.4.3 Amgen Soliris (Eculizumab) Product and Services
9.4.4 Amgen Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Amgen Recent Developments/Updates
9.4.6 Amgen Competitive Strengths & Weaknesses
9.5 Epirus Biopharmaceuticals
9.5.1 Epirus Biopharmaceuticals Details
9.5.2 Epirus Biopharmaceuticals Major Business
9.5.3 Epirus Biopharmaceuticals Soliris (Eculizumab) Product and Services
9.5.4 Epirus Biopharmaceuticals Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Epirus Biopharmaceuticals Recent Developments/Updates
9.5.6 Epirus Biopharmaceuticals Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Soliris (Eculizumab) Industry Chain
10.2 Soliris (Eculizumab) Upstream Analysis
10.2.1 Soliris (Eculizumab) Core Raw Materials
10.2.2 Main Manufacturers of Soliris (Eculizumab) Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Soliris (Eculizumab) Production Mode
10.6 Soliris (Eculizumab) Procurement Model
10.7 Soliris (Eculizumab) Industry Sales Model and Sales Channels
10.7.1 Soliris (Eculizumab) Sales Model
10.7.2 Soliris (Eculizumab) Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Soliris (Eculizumab) Introduction
1.2 World Soliris (Eculizumab) Supply & Forecast
1.2.1 World Soliris (Eculizumab) Production Value (2021 & 2025 & 2032)
1.2.2 World Soliris (Eculizumab) Production (2021-2032)
1.2.3 World Soliris (Eculizumab) Pricing Trends (2021-2032)
1.3 World Soliris (Eculizumab) Production by Region (Based on Production Site)
1.3.1 World Soliris (Eculizumab) Production Value by Region (2021-2032)
1.3.2 World Soliris (Eculizumab) Production by Region (2021-2032)
1.3.3 World Soliris (Eculizumab) Average Price by Region (2021-2032)
1.3.4 North America Soliris (Eculizumab) Production (2021-2032)
1.3.5 Europe Soliris (Eculizumab) Production (2021-2032)
1.3.6 China Soliris (Eculizumab) Production (2021-2032)
1.3.7 Japan Soliris (Eculizumab) Production (2021-2032)
1.3.8 India Soliris (Eculizumab) Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Soliris (Eculizumab) Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Soliris (Eculizumab) Major Market Trends
2 DEMAND SUMMARY
2.1 World Soliris (Eculizumab) Demand (2021-2032)
2.2 World Soliris (Eculizumab) Consumption by Region
2.2.1 World Soliris (Eculizumab) Consumption by Region (2021-2026)
2.2.2 World Soliris (Eculizumab) Consumption Forecast by Region (2027-2032)
2.3 United States Soliris (Eculizumab) Consumption (2021-2032)
2.4 China Soliris (Eculizumab) Consumption (2021-2032)
2.5 Europe Soliris (Eculizumab) Consumption (2021-2032)
2.6 Japan Soliris (Eculizumab) Consumption (2021-2032)
2.7 South Korea Soliris (Eculizumab) Consumption (2021-2032)
2.8 ASEAN Soliris (Eculizumab) Consumption (2021-2032)
2.9 India Soliris (Eculizumab) Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Soliris (Eculizumab) Production Value by Manufacturer (2021-2026)
3.2 World Soliris (Eculizumab) Production by Manufacturer (2021-2026)
3.3 World Soliris (Eculizumab) Average Price by Manufacturer (2021-2026)
3.4 Soliris (Eculizumab) Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Soliris (Eculizumab) Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Soliris (Eculizumab) in 2025
3.5.3 Global Concentration Ratios (CR8) for Soliris (Eculizumab) in 2025
3.6 Soliris (Eculizumab) Market: Overall Company Footprint Analysis
3.6.1 Soliris (Eculizumab) Market: Region Footprint
3.6.2 Soliris (Eculizumab) Market: Company Product Type Footprint
3.6.3 Soliris (Eculizumab) Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Soliris (Eculizumab) Production Value Comparison
4.1.1 United States VS China: Soliris (Eculizumab) Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Soliris (Eculizumab) Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Soliris (Eculizumab) Production Comparison
4.2.1 United States VS China: Soliris (Eculizumab) Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Soliris (Eculizumab) Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Soliris (Eculizumab) Consumption Comparison
4.3.1 United States VS China: Soliris (Eculizumab) Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Soliris (Eculizumab) Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Soliris (Eculizumab) Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.4.3 United States Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
4.5 China Based Soliris (Eculizumab) Manufacturers and Market Share
4.5.1 China Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.5.3 China Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
4.6 Rest of World Based Soliris (Eculizumab) Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Soliris (Eculizumab) Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Soliris (Eculizumab) Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Soliris (Eculizumab) Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Plasma Exchange
5.2.2 Plasma Infusion
5.3 Market Segment by Type
5.3.1 World Soliris (Eculizumab) Production by Type (2021-2032)
5.3.2 World Soliris (Eculizumab) Production Value by Type (2021-2032)
5.3.3 World Soliris (Eculizumab) Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY COMPLEMENT PATHWAY TARGET
6.1 World Soliris (Eculizumab) Market Size Overview by Complement Pathway Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Complement Pathway Target
6.2.1 Paroxysmal Nocturnal Hemoglobinuria
6.2.2 Atypical Hemolytic Uremic Syndrome
6.2.3 Other
6.3 Market Segment by Complement Pathway Target
6.3.1 World Soliris (Eculizumab) Production by Complement Pathway Target (2021-2032)
6.3.2 World Soliris (Eculizumab) Production Value by Complement Pathway Target (2021-2032)
6.3.3 World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2032)
7 MARKET ANALYSIS BY PACKAGE
7.1 World Soliris (Eculizumab) Market Size Overview by Package: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Package
7.2.1 Pre-filled Injections
7.2.2 Vials
7.3 Market Segment by Package
7.3.1 World Soliris (Eculizumab) Production by Package (2021-2032)
7.3.2 World Soliris (Eculizumab) Production Value by Package (2021-2032)
7.3.3 World Soliris (Eculizumab) Average Price by Package (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Soliris (Eculizumab) Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Infusion Therapy
8.2.2 Long-term Maintenance Therapy
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Soliris (Eculizumab) Production by Application (2021-2032)
8.3.2 World Soliris (Eculizumab) Production Value by Application (2021-2032)
8.3.3 World Soliris (Eculizumab) Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Alexion
9.1.1 Alexion Details
9.1.2 Alexion Major Business
9.1.3 Alexion Soliris (Eculizumab) Product and Services
9.1.4 Alexion Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Alexion Recent Developments/Updates
9.1.6 Alexion Competitive Strengths & Weaknesses
9.2 AstraZeneca
9.2.1 AstraZeneca Details
9.2.2 AstraZeneca Major Business
9.2.3 AstraZeneca Soliris (Eculizumab) Product and Services
9.2.4 AstraZeneca Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 AstraZeneca Recent Developments/Updates
9.2.6 AstraZeneca Competitive Strengths & Weaknesses
9.3 Samsung Bioepis
9.3.1 Samsung Bioepis Details
9.3.2 Samsung Bioepis Major Business
9.3.3 Samsung Bioepis Soliris (Eculizumab) Product and Services
9.3.4 Samsung Bioepis Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Samsung Bioepis Recent Developments/Updates
9.3.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.4 Amgen
9.4.1 Amgen Details
9.4.2 Amgen Major Business
9.4.3 Amgen Soliris (Eculizumab) Product and Services
9.4.4 Amgen Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Amgen Recent Developments/Updates
9.4.6 Amgen Competitive Strengths & Weaknesses
9.5 Epirus Biopharmaceuticals
9.5.1 Epirus Biopharmaceuticals Details
9.5.2 Epirus Biopharmaceuticals Major Business
9.5.3 Epirus Biopharmaceuticals Soliris (Eculizumab) Product and Services
9.5.4 Epirus Biopharmaceuticals Soliris (Eculizumab) Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Epirus Biopharmaceuticals Recent Developments/Updates
9.5.6 Epirus Biopharmaceuticals Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Soliris (Eculizumab) Industry Chain
10.2 Soliris (Eculizumab) Upstream Analysis
10.2.1 Soliris (Eculizumab) Core Raw Materials
10.2.2 Main Manufacturers of Soliris (Eculizumab) Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Soliris (Eculizumab) Production Mode
10.6 Soliris (Eculizumab) Procurement Model
10.7 Soliris (Eculizumab) Industry Sales Model and Sales Channels
10.7.1 Soliris (Eculizumab) Sales Model
10.7.2 Soliris (Eculizumab) Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Soliris (Eculizumab) Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Soliris (Eculizumab) Production Value by Region (2021-2026) & (USD Million)
Table 3. World Soliris (Eculizumab) Production Value by Region (2027-2032) & (USD Million)
Table 4. World Soliris (Eculizumab) Production Value Market Share by Region (2021-2026)
Table 5. World Soliris (Eculizumab) Production Value Market Share by Region (2027-2032)
Table 6. World Soliris (Eculizumab) Production by Region (2021-2026) & (K Units)
Table 7. World Soliris (Eculizumab) Production by Region (2027-2032) & (K Units)
Table 8. World Soliris (Eculizumab) Production Market Share by Region (2021-2026)
Table 9. World Soliris (Eculizumab) Production Market Share by Region (2027-2032)
Table 10. World Soliris (Eculizumab) Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Soliris (Eculizumab) Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Soliris (Eculizumab) Major Market Trends
Table 13. World Soliris (Eculizumab) Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Soliris (Eculizumab) Consumption by Region (2021-2026) & (K Units)
Table 15. World Soliris (Eculizumab) Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Soliris (Eculizumab) Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Soliris (Eculizumab) Producers in 2025
Table 18. World Soliris (Eculizumab) Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Soliris (Eculizumab) Producers in 2025
Table 20. World Soliris (Eculizumab) Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Soliris (Eculizumab) Company Evaluation Quadrant
Table 22. World Soliris (Eculizumab) Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Soliris (Eculizumab) Production Site of Key Manufacturer
Table 24. Soliris (Eculizumab) Market: Company Product Type Footprint
Table 25. Soliris (Eculizumab) Market: Company Product Application Footprint
Table 26. Soliris (Eculizumab) Competitive Factors
Table 27. Soliris (Eculizumab) New Entrant and Capacity Expansion Plans
Table 28. Soliris (Eculizumab) Mergers & Acquisitions Activity
Table 29. United States VS China Soliris (Eculizumab) Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Soliris (Eculizumab) Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Soliris (Eculizumab) Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Soliris (Eculizumab) Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 37. China Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Soliris (Eculizumab) Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 42. Rest of World Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Soliris (Eculizumab) Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 47. World Soliris (Eculizumab) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Soliris (Eculizumab) Production by Type (2021-2026) & (K Units)
Table 49. World Soliris (Eculizumab) Production by Type (2027-2032) & (K Units)
Table 50. World Soliris (Eculizumab) Production Value by Type (2021-2026) & (USD Million)
Table 51. World Soliris (Eculizumab) Production Value by Type (2027-2032) & (USD Million)
Table 52. World Soliris (Eculizumab) Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Soliris (Eculizumab) Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Soliris (Eculizumab) Production Value by Complement Pathway Target, (USD Million), 2021 & 2025 & 2032
Table 55. World Soliris (Eculizumab) Production by Complement Pathway Target (2021-2026) & (K Units)
Table 56. World Soliris (Eculizumab) Production by Complement Pathway Target (2027-2032) & (K Units)
Table 57. World Soliris (Eculizumab) Production Value by Complement Pathway Target (2021-2026) & (USD Million)
Table 58. World Soliris (Eculizumab) Production Value by Complement Pathway Target (2027-2032) & (USD Million)
Table 59. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2026) & (US$/Unit)
Table 60. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2027-2032) & (US$/Unit)
Table 61. World Soliris (Eculizumab) Production Value by Package, (USD Million), 2021 & 2025 & 2032
Table 62. World Soliris (Eculizumab) Production by Package (2021-2026) & (K Units)
Table 63. World Soliris (Eculizumab) Production by Package (2027-2032) & (K Units)
Table 64. World Soliris (Eculizumab) Production Value by Package (2021-2026) & (USD Million)
Table 65. World Soliris (Eculizumab) Production Value by Package (2027-2032) & (USD Million)
Table 66. World Soliris (Eculizumab) Average Price by Package (2021-2026) & (US$/Unit)
Table 67. World Soliris (Eculizumab) Average Price by Package (2027-2032) & (US$/Unit)
Table 68. World Soliris (Eculizumab) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Soliris (Eculizumab) Production by Application (2021-2026) & (K Units)
Table 70. World Soliris (Eculizumab) Production by Application (2027-2032) & (K Units)
Table 71. World Soliris (Eculizumab) Production Value by Application (2021-2026) & (USD Million)
Table 72. World Soliris (Eculizumab) Production Value by Application (2027-2032) & (USD Million)
Table 73. World Soliris (Eculizumab) Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Soliris (Eculizumab) Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Alexion Basic Information, Manufacturing Base and Competitors
Table 76. Alexion Major Business
Table 77. Alexion Soliris (Eculizumab) Product and Services
Table 78. Alexion Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Alexion Recent Developments/Updates
Table 80. Alexion Competitive Strengths & Weaknesses
Table 81. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 82. AstraZeneca Major Business
Table 83. AstraZeneca Soliris (Eculizumab) Product and Services
Table 84. AstraZeneca Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. AstraZeneca Recent Developments/Updates
Table 86. AstraZeneca Competitive Strengths & Weaknesses
Table 87. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 88. Samsung Bioepis Major Business
Table 89. Samsung Bioepis Soliris (Eculizumab) Product and Services
Table 90. Samsung Bioepis Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Samsung Bioepis Recent Developments/Updates
Table 92. Samsung Bioepis Competitive Strengths & Weaknesses
Table 93. Amgen Basic Information, Manufacturing Base and Competitors
Table 94. Amgen Major Business
Table 95. Amgen Soliris (Eculizumab) Product and Services
Table 96. Amgen Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Amgen Recent Developments/Updates
Table 98. Amgen Competitive Strengths & Weaknesses
Table 99. Epirus Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 100. Epirus Biopharmaceuticals Major Business
Table 101. Epirus Biopharmaceuticals Soliris (Eculizumab) Product and Services
Table 102. Epirus Biopharmaceuticals Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Epirus Biopharmaceuticals Recent Developments/Updates
Table 104. Epirus Biopharmaceuticals Competitive Strengths & Weaknesses
Table 105. Global Key Players of Soliris (Eculizumab) Upstream (Raw Materials)
Table 106. Global Soliris (Eculizumab) Typical Customers
Table 107. Soliris (Eculizumab) Typical Distributors
Table 1. World Soliris (Eculizumab) Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Soliris (Eculizumab) Production Value by Region (2021-2026) & (USD Million)
Table 3. World Soliris (Eculizumab) Production Value by Region (2027-2032) & (USD Million)
Table 4. World Soliris (Eculizumab) Production Value Market Share by Region (2021-2026)
Table 5. World Soliris (Eculizumab) Production Value Market Share by Region (2027-2032)
Table 6. World Soliris (Eculizumab) Production by Region (2021-2026) & (K Units)
Table 7. World Soliris (Eculizumab) Production by Region (2027-2032) & (K Units)
Table 8. World Soliris (Eculizumab) Production Market Share by Region (2021-2026)
Table 9. World Soliris (Eculizumab) Production Market Share by Region (2027-2032)
Table 10. World Soliris (Eculizumab) Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Soliris (Eculizumab) Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Soliris (Eculizumab) Major Market Trends
Table 13. World Soliris (Eculizumab) Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Soliris (Eculizumab) Consumption by Region (2021-2026) & (K Units)
Table 15. World Soliris (Eculizumab) Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Soliris (Eculizumab) Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Soliris (Eculizumab) Producers in 2025
Table 18. World Soliris (Eculizumab) Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Soliris (Eculizumab) Producers in 2025
Table 20. World Soliris (Eculizumab) Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Soliris (Eculizumab) Company Evaluation Quadrant
Table 22. World Soliris (Eculizumab) Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Soliris (Eculizumab) Production Site of Key Manufacturer
Table 24. Soliris (Eculizumab) Market: Company Product Type Footprint
Table 25. Soliris (Eculizumab) Market: Company Product Application Footprint
Table 26. Soliris (Eculizumab) Competitive Factors
Table 27. Soliris (Eculizumab) New Entrant and Capacity Expansion Plans
Table 28. Soliris (Eculizumab) Mergers & Acquisitions Activity
Table 29. United States VS China Soliris (Eculizumab) Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Soliris (Eculizumab) Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Soliris (Eculizumab) Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Soliris (Eculizumab) Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 37. China Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Soliris (Eculizumab) Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 42. Rest of World Based Soliris (Eculizumab) Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Soliris (Eculizumab) Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Soliris (Eculizumab) Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Soliris (Eculizumab) Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Soliris (Eculizumab) Production Market Share (2021-2026)
Table 47. World Soliris (Eculizumab) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Soliris (Eculizumab) Production by Type (2021-2026) & (K Units)
Table 49. World Soliris (Eculizumab) Production by Type (2027-2032) & (K Units)
Table 50. World Soliris (Eculizumab) Production Value by Type (2021-2026) & (USD Million)
Table 51. World Soliris (Eculizumab) Production Value by Type (2027-2032) & (USD Million)
Table 52. World Soliris (Eculizumab) Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Soliris (Eculizumab) Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Soliris (Eculizumab) Production Value by Complement Pathway Target, (USD Million), 2021 & 2025 & 2032
Table 55. World Soliris (Eculizumab) Production by Complement Pathway Target (2021-2026) & (K Units)
Table 56. World Soliris (Eculizumab) Production by Complement Pathway Target (2027-2032) & (K Units)
Table 57. World Soliris (Eculizumab) Production Value by Complement Pathway Target (2021-2026) & (USD Million)
Table 58. World Soliris (Eculizumab) Production Value by Complement Pathway Target (2027-2032) & (USD Million)
Table 59. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2026) & (US$/Unit)
Table 60. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2027-2032) & (US$/Unit)
Table 61. World Soliris (Eculizumab) Production Value by Package, (USD Million), 2021 & 2025 & 2032
Table 62. World Soliris (Eculizumab) Production by Package (2021-2026) & (K Units)
Table 63. World Soliris (Eculizumab) Production by Package (2027-2032) & (K Units)
Table 64. World Soliris (Eculizumab) Production Value by Package (2021-2026) & (USD Million)
Table 65. World Soliris (Eculizumab) Production Value by Package (2027-2032) & (USD Million)
Table 66. World Soliris (Eculizumab) Average Price by Package (2021-2026) & (US$/Unit)
Table 67. World Soliris (Eculizumab) Average Price by Package (2027-2032) & (US$/Unit)
Table 68. World Soliris (Eculizumab) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Soliris (Eculizumab) Production by Application (2021-2026) & (K Units)
Table 70. World Soliris (Eculizumab) Production by Application (2027-2032) & (K Units)
Table 71. World Soliris (Eculizumab) Production Value by Application (2021-2026) & (USD Million)
Table 72. World Soliris (Eculizumab) Production Value by Application (2027-2032) & (USD Million)
Table 73. World Soliris (Eculizumab) Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Soliris (Eculizumab) Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Alexion Basic Information, Manufacturing Base and Competitors
Table 76. Alexion Major Business
Table 77. Alexion Soliris (Eculizumab) Product and Services
Table 78. Alexion Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Alexion Recent Developments/Updates
Table 80. Alexion Competitive Strengths & Weaknesses
Table 81. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 82. AstraZeneca Major Business
Table 83. AstraZeneca Soliris (Eculizumab) Product and Services
Table 84. AstraZeneca Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. AstraZeneca Recent Developments/Updates
Table 86. AstraZeneca Competitive Strengths & Weaknesses
Table 87. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 88. Samsung Bioepis Major Business
Table 89. Samsung Bioepis Soliris (Eculizumab) Product and Services
Table 90. Samsung Bioepis Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Samsung Bioepis Recent Developments/Updates
Table 92. Samsung Bioepis Competitive Strengths & Weaknesses
Table 93. Amgen Basic Information, Manufacturing Base and Competitors
Table 94. Amgen Major Business
Table 95. Amgen Soliris (Eculizumab) Product and Services
Table 96. Amgen Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Amgen Recent Developments/Updates
Table 98. Amgen Competitive Strengths & Weaknesses
Table 99. Epirus Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 100. Epirus Biopharmaceuticals Major Business
Table 101. Epirus Biopharmaceuticals Soliris (Eculizumab) Product and Services
Table 102. Epirus Biopharmaceuticals Soliris (Eculizumab) Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Epirus Biopharmaceuticals Recent Developments/Updates
Table 104. Epirus Biopharmaceuticals Competitive Strengths & Weaknesses
Table 105. Global Key Players of Soliris (Eculizumab) Upstream (Raw Materials)
Table 106. Global Soliris (Eculizumab) Typical Customers
Table 107. Soliris (Eculizumab) Typical Distributors
LIST OF FIGURES
Figure 1. Soliris (Eculizumab) Picture
Figure 2. World Soliris (Eculizumab) Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Soliris (Eculizumab) Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 5. World Soliris (Eculizumab) Average Price (2021-2032) & (US$/Unit)
Figure 6. World Soliris (Eculizumab) Production Value Market Share by Region (2021-2032)
Figure 7. World Soliris (Eculizumab) Production Market Share by Region (2021-2032)
Figure 8. North America Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 9. Europe Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 10. China Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 11. Japan Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 12. India Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 13. Soliris (Eculizumab) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 16. World Soliris (Eculizumab) Consumption Market Share by Region (2021-2032)
Figure 17. United States Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 18. China Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 19. Europe Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 20. Japan Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 21. South Korea Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 22. ASEAN Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 23. India Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of Soliris (Eculizumab) by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Soliris (Eculizumab) Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Soliris (Eculizumab) Markets in 2025
Figure 27. United States VS China: Soliris (Eculizumab) Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Soliris (Eculizumab) Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Soliris (Eculizumab) Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 31. China Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 33. World Soliris (Eculizumab) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Soliris (Eculizumab) Production Value Market Share by Type in 2025
Figure 35. Plasma Exchange
Figure 36. Plasma Infusion
Figure 37. World Soliris (Eculizumab) Production Market Share by Type (2021-2032)
Figure 38. World Soliris (Eculizumab) Production Value Market Share by Type (2021-2032)
Figure 39. World Soliris (Eculizumab) Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Soliris (Eculizumab) Production Value by Complement Pathway Target, (USD Million), 2021 & 2025 & 2032
Figure 41. World Soliris (Eculizumab) Production Value Market Share by Complement Pathway Target in 2025
Figure 42. Paroxysmal Nocturnal Hemoglobinuria
Figure 43. Atypical Hemolytic Uremic Syndrome
Figure 44. Other
Figure 45. World Soliris (Eculizumab) Production Market Share by Complement Pathway Target (2021-2032)
Figure 46. World Soliris (Eculizumab) Production Value Market Share by Complement Pathway Target (2021-2032)
Figure 47. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2032) & (US$/Unit)
Figure 48. World Soliris (Eculizumab) Production Value by Package, (USD Million), 2021 & 2025 & 2032
Figure 49. World Soliris (Eculizumab) Production Value Market Share by Package in 2025
Figure 50. Pre-filled Injections
Figure 51. Vials
Figure 52. World Soliris (Eculizumab) Production Market Share by Package (2021-2032)
Figure 53. World Soliris (Eculizumab) Production Value Market Share by Package (2021-2032)
Figure 54. World Soliris (Eculizumab) Average Price by Package (2021-2032) & (US$/Unit)
Figure 55. World Soliris (Eculizumab) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Soliris (Eculizumab) Production Value Market Share by Application in 2025
Figure 57. Hospital Infusion Therapy
Figure 58. Long-term Maintenance Therapy
Figure 59. Other
Figure 60. World Soliris (Eculizumab) Production Market Share by Application (2021-2032)
Figure 61. World Soliris (Eculizumab) Production Value Market Share by Application (2021-2032)
Figure 62. World Soliris (Eculizumab) Average Price by Application (2021-2032) & (US$/Unit)
Figure 63. Soliris (Eculizumab) Industry Chain
Figure 64. Soliris (Eculizumab) Procurement Model
Figure 65. Soliris (Eculizumab) Sales Model
Figure 66. Soliris (Eculizumab) Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Soliris (Eculizumab) Picture
Figure 2. World Soliris (Eculizumab) Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Soliris (Eculizumab) Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 5. World Soliris (Eculizumab) Average Price (2021-2032) & (US$/Unit)
Figure 6. World Soliris (Eculizumab) Production Value Market Share by Region (2021-2032)
Figure 7. World Soliris (Eculizumab) Production Market Share by Region (2021-2032)
Figure 8. North America Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 9. Europe Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 10. China Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 11. Japan Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 12. India Soliris (Eculizumab) Production (2021-2032) & (K Units)
Figure 13. Soliris (Eculizumab) Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 16. World Soliris (Eculizumab) Consumption Market Share by Region (2021-2032)
Figure 17. United States Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 18. China Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 19. Europe Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 20. Japan Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 21. South Korea Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 22. ASEAN Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 23. India Soliris (Eculizumab) Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of Soliris (Eculizumab) by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Soliris (Eculizumab) Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Soliris (Eculizumab) Markets in 2025
Figure 27. United States VS China: Soliris (Eculizumab) Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Soliris (Eculizumab) Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Soliris (Eculizumab) Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 31. China Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 32. Rest of World Based Manufacturers Soliris (Eculizumab) Production Market Share 2025
Figure 33. World Soliris (Eculizumab) Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World Soliris (Eculizumab) Production Value Market Share by Type in 2025
Figure 35. Plasma Exchange
Figure 36. Plasma Infusion
Figure 37. World Soliris (Eculizumab) Production Market Share by Type (2021-2032)
Figure 38. World Soliris (Eculizumab) Production Value Market Share by Type (2021-2032)
Figure 39. World Soliris (Eculizumab) Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Soliris (Eculizumab) Production Value by Complement Pathway Target, (USD Million), 2021 & 2025 & 2032
Figure 41. World Soliris (Eculizumab) Production Value Market Share by Complement Pathway Target in 2025
Figure 42. Paroxysmal Nocturnal Hemoglobinuria
Figure 43. Atypical Hemolytic Uremic Syndrome
Figure 44. Other
Figure 45. World Soliris (Eculizumab) Production Market Share by Complement Pathway Target (2021-2032)
Figure 46. World Soliris (Eculizumab) Production Value Market Share by Complement Pathway Target (2021-2032)
Figure 47. World Soliris (Eculizumab) Average Price by Complement Pathway Target (2021-2032) & (US$/Unit)
Figure 48. World Soliris (Eculizumab) Production Value by Package, (USD Million), 2021 & 2025 & 2032
Figure 49. World Soliris (Eculizumab) Production Value Market Share by Package in 2025
Figure 50. Pre-filled Injections
Figure 51. Vials
Figure 52. World Soliris (Eculizumab) Production Market Share by Package (2021-2032)
Figure 53. World Soliris (Eculizumab) Production Value Market Share by Package (2021-2032)
Figure 54. World Soliris (Eculizumab) Average Price by Package (2021-2032) & (US$/Unit)
Figure 55. World Soliris (Eculizumab) Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Soliris (Eculizumab) Production Value Market Share by Application in 2025
Figure 57. Hospital Infusion Therapy
Figure 58. Long-term Maintenance Therapy
Figure 59. Other
Figure 60. World Soliris (Eculizumab) Production Market Share by Application (2021-2032)
Figure 61. World Soliris (Eculizumab) Production Value Market Share by Application (2021-2032)
Figure 62. World Soliris (Eculizumab) Average Price by Application (2021-2032) & (US$/Unit)
Figure 63. Soliris (Eculizumab) Industry Chain
Figure 64. Soliris (Eculizumab) Procurement Model
Figure 65. Soliris (Eculizumab) Sales Model
Figure 66. Soliris (Eculizumab) Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
